Millipore Sigma Vibrant Logo
Atención: Nos hemos mudado. Los productos Merck Millipore ya no pueden adquirirse en MerckMillipore.comMás información

MAB5382 Anti-Hypoxia Inducible Factor 1 α Antibody, clone H1α67

MAB5382
100 µg  
Purchase on Sigma-Aldrich

Ofertas especiales

Descripción

Replacement Information

Ofertas especiales

Tabla espec. clave

Species ReactivityKey ApplicationsHostFormatAntibody Type
Ft, H, M, REMSA, IHC, IP, WBMPurifiedMonoclonal Antibody
Description
Catalogue NumberMAB5382
Replaces04-1006
Brand Family Chemicon®
Trade Name
  • Chemicon
DescriptionAnti-Hypoxia Inducible Factor 1 α Antibody, clone H1α67
Alternate Names
  • HIF-1 alpha
  • ARNT Interacting Protein
  • MOP1
Background InformationHIF is a transcriptional complex that plays a central role in mammalian oxygen homeostasis, the posttranslational modification by prolyl hydroxylation as a key regulatory event that targets HIF-alpha subunits for proteasomal destruction via the von Hippel-Lindau ubiquitylation complex. The transcriptional complex is composed of an alpha-beta heterodimer; HIF-beta being a constitutive nuclear protein that dimerises with oxygen regulated HIF-alpha subunits. In normoxia, 4-hydroxylation of human HIF-alpha at Pro402 or Pro564 by a set of HIF prolyl hydroxylase isoenzymes (PHD 1-3) mediates HIF1-alpha recognition by von Hippel-Lindau ubiquitin ligase complex leading to its proteasomal destruction. In hypoxia (deprivation of oxygen), lack of hydroxylase activity enables HIF-alpha subunits to escape destruction and become transcriptionally active. Thus HIF hydroxylases provide a focus for understanding cellular responses to hypoxia and target for therapeutic manipulation. There are several HIF factors, which include HIF 1-alpha, HIF 1-beta, HIF 2-alpha. HIF 1-alpha is an 812 a.a. protein in rat and 836 a.a. long in mouse and human. A master transcriptional regulator of the adaptive response to hypoxia. Under hypoxic conditions activates the transcription of over 40 genes, including, erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. Plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. It is ubiquitous in expression as cytoplasmic in normoxia, nuclear translocation in response to hypoxia.
References
Product Information
FormatPurified
Control
  • Cobalt chloride-treated MCF-7 cells
PresentationProtein A Purified mouse immunoglobulin in 20 mM sodium phosphate, 250 mM NaCl, pH. 7.6, with 0.1% sodium azide as a preservative.
Quality LevelMQ100
Applications
ApplicationAnti-Hypoxia Inducible Factor 1 α Antibody, clone H1α67 is a Mouse Monoclonal Antibody for detection of Hypoxia Inducible Factor 1 α also known as HIF-1 alpha or ARNT Interacting Protein & has been validated in EMSA, IHC, IP & WB.
Key Applications
  • Electrophoretic Mobility Shift Assay
  • Immunohistochemistry
  • Immunoprecipitation
  • Western Blotting
Application NotesWestern blot: 1:500-1:1,000. The antibody recognizes a band of 120 kD in induced tissues and cells. Multiple bands may be present at 120 kD representing post-translational modification of HIF-1alpha.

Immunohistochemistry: 1:500-1:1,000. The antibody has been used successfully on formalin-fixed, paraffin embedded tissue sections after antigen retrieval.

Immunoprecipitation

Gel Shift

Optimal working dilutions must be determined by end user.
Biological Information
ImmunogenFusion protein from amino acids 432-528 of human HIF-1alpha.
CloneH1alpha67
ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
HostMouse
SpecificityRecognizes Hypoxia inducible factor-1alpha (HIF-1alpha).
IsotypeIgG2b
Species Reactivity
  • Ferret
  • Human
  • Mouse
  • Rat
Antibody TypeMonoclonal Antibody
Entrez Gene Number
Entrez Gene SummaryHypoxia-inducible factor-1 (HIF1) is a transcription factor found in mammalian cells cultured under reduced oxygen tension that plays an essential role in cellular and systemic homeostatic responses to hypoxia. HIF1 is a heterodimer composed of an alpha subunit and a beta subunit. The beta subunit has been identified as the aryl hydrocarbon receptor nuclear translocator (ARNT). This gene encodes the alpha subunit of HIF-1. Overexpression of a natural antisense transcript (aHIF) of this gene has been shown to be associated with nonpapillary renal carcinomas. Two alternative transcripts encoding different isoforms have been identified.
Gene Symbol
  • HIF1A
  • HIF-1ALPHA
  • HIF-1alpha
  • MOP1
  • PASD8
  • HIF1-ALPHA
  • HIF1
Purification MethodProtein A Purfied
UniProt Number
UniProt SummaryFUNCTION: SwissProt: Q16665 # Functions as a master transcriptional regulator of the adaptive response to hypoxia. Under hypoxic conditions activates the transcription of over 40 genes, including, erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. Plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. Binds to core DNA sequence 5'-[AG]CGTG-3' within the hypoxia response element (HRE) of target gene promoters. Activation requires recruitment of transcriptional coactivators such as CREBPB and EP300. Activity is enhanced by interaction with both, NCOA1 or NCOA2. Interaction with redox regulatory protein APEX seems to activate CTAD and potentiates activation by NCOA1 and CREBBP.
SIZE: 826 amino acids; 92670 Da
SUBUNIT: Interacts with COPS5 subunit of COP9 signalosome complex, leading to the regulation of its stability. Interacts with TSGA10 (By similarity). Efficient DNA binding requires heterodimerization of an alpha and a beta/ARNT subunit. Binds to the TAZ-type 1 domains of CREBBP and EP300. Interacts with NCOA1, NCOA2, APEX and HSP90. Interacts with VHL which docks HFA1 to the E3 ubiquitin ligase complex for subsequent destruction. Interaction, via the ODD domain, with the beta domain of VHLL, protects HIF1A from destruction by competing against the destructive targeting initiated by VHL.
SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Cytoplasmic in normoxia, nuclear translocation in response to hypoxia.
TISSUE SPECIFICITY: Expressed in most tissues with highest levels in kidney and heart. Overexpressed in the majority of common human cancers and their metastases, due to the presence of intratumoral hypoxia and as a result of mutations in genes encoding oncoproteins and tumor suppressors.DOMAIN:SwissProt: Q16665 Contains two independent C-terminal transactivation domains, NTAD and CTAD, which function synergistically. Their transcriptional activity is repressed by an intervening inhibitory domain (ID).
PTM: In normoxia, is hydroxylated on Pro-402 and Pro-564 in the oxygen-dependent degradation domain (ODD) by EGLN1/PHD1 and EGLN2/PHD2. EGLN3/PHD3 has also been shown to hydroxylate Pro-564. The hydroxylated prolines promote interaction with VHL, initiating rapid ubiquitination and subsequent proteasomal degradation. Under hypoxia, proline hydroxylation is impaired and ubiquitination is attenuated, resulting in stabilization. & In normoxia, is hydroxylated on Asn-803 by HIF1AN, thus abrogating interaction with CREBBP and EP300 and preventing transcriptional activation. & S-nitrosylation of Cys-800 may be responsible for increased recruitment of p300 coactivator necessary for transcriptional activity of HIF-1 complex. & Acetylation of Lys-532 by ARD1 increases interaction with VHL and stimulates subsequent proteasomal degradation. & Requires phosphorylation for DNA-binding.
SIMILARITY: Contains 1 basic helix-loop-helix (bHLH) domain. & Contains 1 PAC (PAS-associated C-terminal) domain. & Contains 2 PAS (PER-ARNT-SIM) domains.
Molecular WeightPredicted MW: 96 kDa, apparent MW: 120 kDa
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsMaintain for 1 year at 2–8°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Packaging Information
Material Size100 µg
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Número de referencia GTIN
MAB5382 04053252267956

Documentation

Anti-Hypoxia Inducible Factor 1 α Antibody, clone H1α67 Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Anti-Hypoxia Inducible Factor 1 α Antibody, clone H1α67 Certificados de análisis

CargoNúmero de lote
Anti-Hypoxia Inducible Factor 1 , clone H167 - 2204901 2204901
Anti-Hypoxia Inducible Factor 1 , clone H167 - 2287162 2287162
Anti-Hypoxia Inducible Factor 1 , clone H167 - LV1766465 LV1766465
Anti-Hypoxia Inducible Factor 1 α, -2658939 2658939
Anti-Hypoxia Inducible Factor 1 α, clone H1α67 - 2343385 2343385
Anti-Hypoxia Inducible Factor 1 α, clone H1α67 - 2387840 2387840
Anti-Hypoxia Inducible Factor 1 α, clone H1α67 - 3590808 3590808
Anti-Hypoxia Inducible Factor 1 α, clone H1α67 - 3785967 3785967
Anti-Hypoxia Inducible Factor 1 α, clone H1α67 - 3849575 3849575
Anti-Hypoxia Inducible Factor 1 α, clone H1α67 - 3882012 3882012

Referencias bibliográficas

Visión general referenciasAplicación EspeciePub Med ID
Epigenetics of hypoxic pulmonary arterial hypertension following intrauterine growth retardation rat: epigenetics in PAH following IUGR.
Xu, XF; Lv, Y; Gu, WZ; Tang, LL; Wei, JK; Zhang, LY; Du, LZ
Respiratory research  14  20  2013

Mostrar resumen
23406533 23406533
Molecular prognostic prediction for locally advanced nasopharyngeal carcinoma by support vector machine integrated approach.
Wan, XB; Zhao, Y; Fan, XJ; Cai, HM; Zhang, Y; Chen, MY; Xu, J; Wu, XY; Li, HB; Zeng, YX; Hong, MH; Liu, Q
PloS one  7  e31989  2011

Mostrar resumen
22427815 22427815
Neuroprotection of neurotrophin-3 against focal cerebral ischemia/reperfusion injury is regulated by hypoxia-responsive element in rats.
J Zhang,Q Shi,P Yang,X Xu,X Chen,C Qi,H Lu,B Zhao,P Zheng,P Zhang,Y Liu
Neuroscience  222  2011

Mostrar resumen
22820262 22820262
Oxygen regulation of the epithelial Na channel in the collecting duct.
Husted, RF; Lu, H; Sigmund, RD; Stokes, JB
American journal of physiology. Renal physiology  300  F412-24  2010

Mostrar resumen
21123494 21123494
The podocyte protein nephrin is required for cardiac vessel formation.
Wagner, N; Morrison, H; Pagnotta, S; Michiels, JF; Schwab, Y; Tryggvason, K; Schedl, A; Wagner, KD
Human molecular genetics  20  2182-94  2010

Mostrar resumen
21402589 21402589
Presenilin-1 regulates induction of hypoxia inducible factor-1α: altered activation by a mutation associated with familial Alzheimer's disease.
De Gasperi, R; Sosa, MA; Dracheva, S; Elder, GA
Molecular neurodegeneration  5  38  2009

Mostrar resumen
20863403 20863403
Regulation of sodium transporters in the kidney during cyclosporine treatment.
Damiano S, Scanni R, Ciarcia R, Florio S, Capasso G
J Nephrol  S191-8.  2009

Mostrar resumen
21170880 21170880
Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis.
Yanislav Kolev, Hiroyuki Uetake, Yoko Takagi, Kenichi Sugihara, Yanislav Kolev, Hiroyuki Uetake, Yoko Takagi, Kenichi Sugihara
Annals of surgical oncology  15  2336-44  2008

Mostrar resumen
18521687 18521687
Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-gluco-RGD autoradiography.
Esther G C Troost, Peter Laverman, Johannes H A M Kaanders, Wim J G Oyen, Otto C Boerman, Johan Bussink
Journal of nuclear medicine : official publication, Society of Nuclear Medicine  49  1732; author reply 1732-3  2008

18794277 18794277
Bioimaging assessment and effect of skin wound healing using bone-marrow-derived mesenchymal stromal cells with the artificial dermis in diabetic rats.
Hirokazu Inoue, Takashi Murakami, Takashi Ajiki, Mayumi Hara, Yuichi Hoshino, Eiji Kobayashi, Hirokazu Inoue, Takashi Murakami, Takashi Ajiki, Mayumi Hara, Yuichi Hoshino, Eiji Kobayashi, Hirokazu Inoue, Takashi Murakami, Takashi Ajiki, Mayumi Hara, Yuichi Hoshino, Eiji Kobayashi
Journal of biomedical optics  13  064036  2008

Mostrar resumen
19123682 19123682

Folleto

Cargo
Advancing cancer research: From hallmarks & biomarkers to tumor microenvironment progression